Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Basic Research of Hepatopancreatobillary Tumor
share announcement

Basic Research of Hepatopancreatobillary Tumor

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: closed (5 May 2024) | Viewed by 2762

Special Issue Editors

Prof. Dr. Lianxin Liu

E-Mail Website
Guest Editor
Department of Hepatobiliary Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China
Interests: hepatobiliary and pancreatic tumors
Prof. Dr. Yingbin Liu

E-Mail Website
Guest Editor
Renji Hospital, Shanghai Jiaotong University, Shanghai, China
Interests: development and treatment of hepatobiliary and pancreatic malignancies; surgical treatment of malignant tumors of the digestive system; early diagnosis of gallbladder cancer
Prof. Dr. Paul J. Chiao

E-Mail Website
Guest Editor
Department of Molecular and Cellular Oncology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Interests: the signaling pathway of NF-κB transcription factor and the role of NF-κB in cancer; anti-apoptosis; inflammation and immune response, and the feedback regulation mechanism of NF-κB and IκBα

Special Issue Information

Dear Colleagues,

We are pleased to invite you or your promising young colleagues to make a valuable contribution to the Special Issue of Cancers titled “Basic research on Hepatopancreatobillary Tumors”.

Over the past several decades, primary liver cancer (PLC), pancreatic cancer, and gallbladder cancer have become the focus of rising concern mainly due to the increasing rates of incidence and high global mortality. Anatomically, the primary sites of these three types of cancer are adjacent to each other. However, the mechanisms of these tumors’ development are different. A number of mechanisms have been shown to be involved in tumorigenesis, tumor development, and tumor metastasis. Today, the tumor microenvironment appears to be highly involved in the tumor pathological condition and poor prognosis. There has been no major breakthrough in drug treatment for hepatopancreatobillary tumor in recent 10 years. Recently, diversity and heterogeneity in the tumor microenvironment have attracted attention. New technology developments bring more opportunities for scientists to understand tumor heterogeneity and new therapy. After resolving the immune microenvironment within the tumor, targeted therapy and immunotherapy become more promising. However, after the application of targeted therapy and immunotherapy, hepatobiliary and pancreatic tumors quickly develop drug resistance. The underlying drug resistance and immune escape mechanisms of tumors also need to be urgently investigated.

To summarize, we focus on basic research in hepatobiliary and pancreatic tumors. This Special Issue aims to bring together current findings and opinions in many aspects of the hepatopancreatobillary tumor to provide clues for tumorigenesis, tumor development, tumor metastasis, and tumor therapy in this field.

Original research articles and reviews are welcome in this Special Issue. We aim to study the mechanisms of hepatopancreatobillary tumors. Research areas may include (but are not limited to) the following: tumorigenesis, tumor proliferation, tumor therapy target, tumor drug resistance, tumor metabolism, and the tumor immune microenvironment.

We look forward to receiving your contributions.

Prof. Dr. Lianxin Liu
Prof. Dr. Yingbin Liu
Prof. Dr. Paul J. Chiao
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • liver cancer
  • gallbladder cancer
  • pancreatic cancer
  • microenvironment
  • drug resistant

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

16 pages, 11135 KiB  
Article
Mismatch Repair Deficiency Is a Prognostic Factor Predicting Good Survival of Opisthorchis viverrini-Associated Cholangiocarcinoma at Early Cancer Stage
by Natcha Khuntikeo, Sureerat Padthaisong, Watcharin Loilome, Poramate Klanrit, Soontaree Ratchatapusit, Anchalee Techasen, Apiwat Jareanrat, Vasin Thanasukarn, Tharatip Srisuk, Vor Luvira, Jarin Chindaprasirt, Prakasit Sa-ngiamwibool, Chaiwat Aphivatanasiri, Piyapharom Intarawichian, Supinda Koonmee, Piya Prajumwongs and Attapol Titapun
Cancers 2023, 15(19), 4831; https://doi.org/10.3390/cancers15194831 - 2 Oct 2023
Cited by 1 | Viewed by 1327
Abstract
Background: The mismatch repair (MMR) system prevents DNA mutation; therefore, deficient MMR protein (dMMR) expression causes genetic alterations and microsatellite instability (MSI). dMMR is correlated with a good outcome and treatment response in various cancers; however, the situation remains ambiguous in cholangiocarcinoma (CCA). [...] Read more.
Background: The mismatch repair (MMR) system prevents DNA mutation; therefore, deficient MMR protein (dMMR) expression causes genetic alterations and microsatellite instability (MSI). dMMR is correlated with a good outcome and treatment response in various cancers; however, the situation remains ambiguous in cholangiocarcinoma (CCA). This study aims to evaluate the prevalence of dMMR and investigate the correlation with clinicopathological features and the survival of CCA patients after resection. Materials and Methods: Serum and tissues were collected from CCA patients who underwent resection from January 2005 to December 2017. Serum OV IgG was examined using ELISA. The expression of MMR proteins MLH1, MSH2, MSH6 and PMS2 was investigated by immunohistochemistry; subsequently, MMR assessment was evaluated as either proficient or as deficient by pathologists. The clinicopathological features and MMR status were compared using the Chi-square test. Univariate and multivariate analyses were conducted to identify prognostic factors. Results: Among the 102 CCA patients, dMMR was detected in 22.5%. Survival analysis revealed that dMMR patients had better survival than pMMR (HR = 0.50, p = 0.008). In multivariate analysis, dMMR was an independent factor for a good prognosis in CCA patients (HR = 0.58, p = 0.041), especially at an early stage (HR = 0.18, p = 0.027). Moreover, subgroup analysis showed dMMR patients who received adjuvant chemotherapy had better survival than surgery alone (HR = 0.28, p = 0.012). Conclusion: This study showed a high prevalence of dMMR in cholangiocarcinoma with dMMR being the independent prognostic factor for good survival, especially in early-stage CCA and for patients who received adjuvant chemotherapy. dMMR should be the marker for selecting patients to receive a specific adjuvant treatment after resection for CCA. Full article
(This article belongs to the Special Issue Basic Research of Hepatopancreatobillary Tumor)
►▼ Show Figures

Figure 1

Other

Jump to: Research

19 pages, 3843 KiB  
Systematic Review
The Current Evidence of Intensity-Modulated Radiotherapy for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
by Won Il Jang, Sunmi Jo, Ji Eun Moon, Sun Hyun Bae and Hee Chul Park
Cancers 2023, 15(20), 4914; https://doi.org/10.3390/cancers15204914 - 10 Oct 2023
Cited by 1 | Viewed by 1107
Abstract
Intensity-modulated radiotherapy (IMRT), an advanced RT technique, is a considerable treatment option for hepatocellular carcinoma (HCC). However, the distinguishing features of IMRT for HCC have not yet been clearly defined. A systematic review was performed according to the guidelines of the Preferred Reporting [...] Read more.
Intensity-modulated radiotherapy (IMRT), an advanced RT technique, is a considerable treatment option for hepatocellular carcinoma (HCC). However, the distinguishing features of IMRT for HCC have not yet been clearly defined. A systematic review was performed according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. The PubMed/MedLine, Embase, Cochrane Library, Web of Science, and KoreaMed were used to screen eligible studies focusing on treatment outcomes after IMRT for HCC until 18 April 2023. A total of 1755 HCC patients receiving IMRT among 29 studies from 2009 to 2023 were selected for the meta-analysis. The median proportion of Barcelona Clinic Liver Cancer stage C was 100% (range: 38–100%). Nineteen studies used combined treatment. Pooled rates of response and 1-year local control were 58% (95% confidence interval [CI], 50–65%) and 84% (95% CI, 70–94%), respectively. The median overall survival (OS) was 13 months (range: 5–45 months), and pooled 1- and 3-year OS rates were 59% (95% CI, 52–66%), and 23% (95% CI, 14–33%), respectively. Pooled rates of classic radiation-induced liver disease (RILD), nonclassic RILD, and hepatic toxicity ≥ grade 3 were 2%, 4%, and 4%, respectively. Although most patients had advanced-stage HCC and combined treatment was commonly used, IMRT for HCC showed similar survival to existing RT modalities and relatively low severe toxicity. Full article
(This article belongs to the Special Issue Basic Research of Hepatopancreatobillary Tumor)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop